Bivalent SMAC mimetic APG-1387 reduces HIV reservoirs and limits viral rebound in humanized mice

Summary: Latent viral reservoirs (VRs) represent a main barrier to HIV cure. Thus, developing new approaches that can purge and eliminate VRs paves the path toward achieving an HIV-1 cure. APG-1387, a bivalent SMAC mimetic (SM), efficiently reactivates latent HIV expression in T cell line models and...

Full description

Saved in:
Bibliographic Details
Main Authors: Jaspreet Jain, Tram N.Q. Pham, Sharmin Begum, Maria Carmen Romero-Medina, Nicolas Bellini, Yuanyi Li, Frédéric Dallaire, Kathie Béland, Natasha Patey, Jean V. Guimond, Élie Haddad, Yifan Zhai, Éric A. Cohen
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:iScience
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S258900422402697X
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846113091586097152
author Jaspreet Jain
Tram N.Q. Pham
Sharmin Begum
Maria Carmen Romero-Medina
Nicolas Bellini
Yuanyi Li
Frédéric Dallaire
Kathie Béland
Natasha Patey
Jean V. Guimond
Élie Haddad
Yifan Zhai
Éric A. Cohen
author_facet Jaspreet Jain
Tram N.Q. Pham
Sharmin Begum
Maria Carmen Romero-Medina
Nicolas Bellini
Yuanyi Li
Frédéric Dallaire
Kathie Béland
Natasha Patey
Jean V. Guimond
Élie Haddad
Yifan Zhai
Éric A. Cohen
author_sort Jaspreet Jain
collection DOAJ
description Summary: Latent viral reservoirs (VRs) represent a main barrier to HIV cure. Thus, developing new approaches that can purge and eliminate VRs paves the path toward achieving an HIV-1 cure. APG-1387, a bivalent SMAC mimetic (SM), efficiently reactivates latent HIV expression in T cell line models and enhances active caspase 3 expression, a condition that typically leads to apoptosis. In primary CD4+ T cells infected with a dual reporter-encoded HIV, APG-1387 decreases latently infected cells without a notable effect on productively infected cells. In virally suppressed humanized (hu)-BLT mice, APG-1387 augments cell-associated viral RNA and potently reduces HIV DNA-containing cells without modulating T cell activation or proliferation. Upon antiretroviral therapy (ART) interruption, HIV rebound was decreased in APG-1387-treated humanized mice (hu-mice), and the viremia maintained at levels below that of pre-ART. Thus, the ability of APG-1387 to affect VRs and decrease viral rebound highlights the potential of bivalent SMs in HIV cure strategies.
format Article
id doaj-art-b2419a44a52a4d4982d6d7e0a8ba0880
institution Kabale University
issn 2589-0042
language English
publishDate 2024-12-01
publisher Elsevier
record_format Article
series iScience
spelling doaj-art-b2419a44a52a4d4982d6d7e0a8ba08802024-12-22T05:29:28ZengElsevieriScience2589-00422024-12-012712111470Bivalent SMAC mimetic APG-1387 reduces HIV reservoirs and limits viral rebound in humanized miceJaspreet Jain0Tram N.Q. Pham1Sharmin Begum2Maria Carmen Romero-Medina3Nicolas Bellini4Yuanyi Li5Frédéric Dallaire6Kathie Béland7Natasha Patey8Jean V. Guimond9Élie Haddad10Yifan Zhai11Éric A. Cohen12Institut de Recherches Cliniques de Montréal (IRCM), Montréal, QC H2W 1R7, Canada; Division of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, Montréal, QC H4A 3J1, CanadaInstitut de Recherches Cliniques de Montréal (IRCM), Montréal, QC H2W 1R7, Canada; Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montréal, QC H3T 1J4, CanadaInstitut de Recherches Cliniques de Montréal (IRCM), Montréal, QC H2W 1R7, Canada; Division of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, Montréal, QC H4A 3J1, CanadaInstitut de Recherches Cliniques de Montréal (IRCM), Montréal, QC H2W 1R7, Canada; Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montréal, QC H3T 1J4, CanadaInstitut de Recherches Cliniques de Montréal (IRCM), Montréal, QC H2W 1R7, Canada; Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montréal, QC H3T 1J4, CanadaCHU Sainte-Justine Azrieli Research Center, Montréal, QC H3T 1C5, CanadaInstitut de Recherches Cliniques de Montréal (IRCM), Montréal, QC H2W 1R7, CanadaCHU Sainte-Justine Azrieli Research Center, Montréal, QC H3T 1C5, CanadaCHU Sainte-Justine Azrieli Research Center, Montréal, QC H3T 1C5, Canada; Department of Pathology and Cellular Biology, Université de Montréal, Montréal, QC H3T 1J4, CanadaCentre de Santé et de Services Sociaux Jeanne-Mance, Montréal, QC H2X 1K6, CanadaDepartment of Microbiology, Infectiology and Immunology, Université de Montréal, Montréal, QC H3T 1J4, Canada; CHU Sainte-Justine Azrieli Research Center, Montréal, QC H3T 1C5, Canada; Department of Pediatrics, Université de Montréal, Montréal, QC H3T 1J4, CanadaAscentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu 215000, China; Ascentage Pharma Group, Rockville, MD 20850, USAInstitut de Recherches Cliniques de Montréal (IRCM), Montréal, QC H2W 1R7, Canada; Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montréal, QC H3T 1J4, Canada; Corresponding authorSummary: Latent viral reservoirs (VRs) represent a main barrier to HIV cure. Thus, developing new approaches that can purge and eliminate VRs paves the path toward achieving an HIV-1 cure. APG-1387, a bivalent SMAC mimetic (SM), efficiently reactivates latent HIV expression in T cell line models and enhances active caspase 3 expression, a condition that typically leads to apoptosis. In primary CD4+ T cells infected with a dual reporter-encoded HIV, APG-1387 decreases latently infected cells without a notable effect on productively infected cells. In virally suppressed humanized (hu)-BLT mice, APG-1387 augments cell-associated viral RNA and potently reduces HIV DNA-containing cells without modulating T cell activation or proliferation. Upon antiretroviral therapy (ART) interruption, HIV rebound was decreased in APG-1387-treated humanized mice (hu-mice), and the viremia maintained at levels below that of pre-ART. Thus, the ability of APG-1387 to affect VRs and decrease viral rebound highlights the potential of bivalent SMs in HIV cure strategies.http://www.sciencedirect.com/science/article/pii/S258900422402697XImmunologyVirologyNatural sciencesBiological sciences
spellingShingle Jaspreet Jain
Tram N.Q. Pham
Sharmin Begum
Maria Carmen Romero-Medina
Nicolas Bellini
Yuanyi Li
Frédéric Dallaire
Kathie Béland
Natasha Patey
Jean V. Guimond
Élie Haddad
Yifan Zhai
Éric A. Cohen
Bivalent SMAC mimetic APG-1387 reduces HIV reservoirs and limits viral rebound in humanized mice
iScience
Immunology
Virology
Natural sciences
Biological sciences
title Bivalent SMAC mimetic APG-1387 reduces HIV reservoirs and limits viral rebound in humanized mice
title_full Bivalent SMAC mimetic APG-1387 reduces HIV reservoirs and limits viral rebound in humanized mice
title_fullStr Bivalent SMAC mimetic APG-1387 reduces HIV reservoirs and limits viral rebound in humanized mice
title_full_unstemmed Bivalent SMAC mimetic APG-1387 reduces HIV reservoirs and limits viral rebound in humanized mice
title_short Bivalent SMAC mimetic APG-1387 reduces HIV reservoirs and limits viral rebound in humanized mice
title_sort bivalent smac mimetic apg 1387 reduces hiv reservoirs and limits viral rebound in humanized mice
topic Immunology
Virology
Natural sciences
Biological sciences
url http://www.sciencedirect.com/science/article/pii/S258900422402697X
work_keys_str_mv AT jaspreetjain bivalentsmacmimeticapg1387reduceshivreservoirsandlimitsviralreboundinhumanizedmice
AT tramnqpham bivalentsmacmimeticapg1387reduceshivreservoirsandlimitsviralreboundinhumanizedmice
AT sharminbegum bivalentsmacmimeticapg1387reduceshivreservoirsandlimitsviralreboundinhumanizedmice
AT mariacarmenromeromedina bivalentsmacmimeticapg1387reduceshivreservoirsandlimitsviralreboundinhumanizedmice
AT nicolasbellini bivalentsmacmimeticapg1387reduceshivreservoirsandlimitsviralreboundinhumanizedmice
AT yuanyili bivalentsmacmimeticapg1387reduceshivreservoirsandlimitsviralreboundinhumanizedmice
AT fredericdallaire bivalentsmacmimeticapg1387reduceshivreservoirsandlimitsviralreboundinhumanizedmice
AT kathiebeland bivalentsmacmimeticapg1387reduceshivreservoirsandlimitsviralreboundinhumanizedmice
AT natashapatey bivalentsmacmimeticapg1387reduceshivreservoirsandlimitsviralreboundinhumanizedmice
AT jeanvguimond bivalentsmacmimeticapg1387reduceshivreservoirsandlimitsviralreboundinhumanizedmice
AT eliehaddad bivalentsmacmimeticapg1387reduceshivreservoirsandlimitsviralreboundinhumanizedmice
AT yifanzhai bivalentsmacmimeticapg1387reduceshivreservoirsandlimitsviralreboundinhumanizedmice
AT ericacohen bivalentsmacmimeticapg1387reduceshivreservoirsandlimitsviralreboundinhumanizedmice